RE:RE:ValuationVerusSemperSors wrote
The Theralase website has a presentation where they size the market opportunity. They calculate:
240,000 (New Bladder Cancer Cases/year in US, Canada & Europe) x 70% (NMIBC) x 30% (BCG Unresponsive) x 1/2 (half the potential market?) x $50,000 (Based on "willingness to pay" of $50-150,000) = $1.1 billion (my caclulator says $1.26 billion)
Looking at the new world cases that number rises.
The new data estimates that 573,278 people will be diagnosed with bladder cancer in 2020 around the world, placing bladder cancer as the 10th most commonly diagnosed cancer in the world. The new data projects an estimated 440,864 new cases of bladder cancer in men worldwide, accounting for 4.4% of total new cases.Dec 14, 2020
As the likelihood of Theralase becoming a productive commercialized company with a partner or licensed member of Theralase is still a question as to which will direction they will take! Bladder Cancer is the 10th most common of the cancers. Should Theralase capture 5%, 10% or 15% in their first year of communication in my opinion is " yes " it depends greatly on the doctors & hospitals being aware of their success.
I also have faith that the news media will be putting this story in as the Breaking News at the beginning of their newscast.